hs-CRP Interpreter.

High-sensitivity C-reactive protein is a liver-produced acute-phase protein that rises 100–1000× during acute infection, injury, or inflammation. The "high-sensitivity" version of the assay measures the small chronic baseline that distinguishes low-grade systemic inflammation from normal — and that chronic baseline is what independently predicts cardiovascular events.

hs-CRP is not a cause of atherosclerosis per se — it is a downstream marker of the inflammation that drives plaque formation. But its predictive power is strong enough that Paul Ridker and the JUPITER trial group built an entire treatment paradigm around it.

In 17,802 apparently healthy adults with normal LDL (<130 mg/dL) but hs-CRP ≥ 2.0 mg/L, rosuvastatin 20 mg reduced the primary composite endpoint (MI, stroke, cardiovascular death, revascularization, unstable angina) by 44% vs placebo over a median 1.9 years (Ridker NEJM 2008). The trial was stopped early for benefit. JUPITER established the principle that elevated hs-CRP identifies a population that benefits from statin therapy *independent of their LDL*.

The 2018 AHA/ACC cholesterol guideline now lists hs-CRP ≥ 2 mg/L as a "risk-enhancing factor" that should tilt borderline statin decisions toward treatment in adults aged 40–75 with intermediate 10-year ASCVD risk.

hs-CRP has a 19-hour half-life. It rises within 6 hours of an inflammatory trigger and stays elevated for days to weeks. Recent infections (including viral), surgery, injury, vaccination, and active autoimmune disease all push hs-CRP up — and a single elevated reading during one of these events does not reflect chronic cardiovascular risk.

Best practice from the 2003 AHA/CDC scientific statement: for cardiovascular risk assessment, hs-CRP should be measured at least twice, 2 weeks apart, in a metabolically stable state (no recent illness). Values >10 mg/L should trigger a workup for the acute cause, not a cardiovascular risk interpretation.

hs-CRP responds robustly to lifestyle changes. The biggest movers, in approximate order of effect size:

(1) Weight loss — 30–40% reduction with 5–10% weight loss, especially visceral fat. (2) Aerobic + resistance training — 150+ min/wk moderate-intensity exercise drops hs-CRP independent of weight. (3) Mediterranean-style diet — PREDIMED showed 20–30% reductions vs control. (4) Statin therapy — 15–25% drop independent of LDL effect. (5) Smoking cessation — smokers run 2–3× higher hs-CRP; quitting normalizes within 6–12 months. (6) Sleep quality and stress management — chronic sleep restriction and unmanaged stress drive IL-6 and CRP up via cortisol and sympathetic activation. (7) Treat periodontal disease — gum infection is a surprisingly common driver of chronic low-grade systemic hs-CRP.

Persistently elevated hs-CRP (>3 mg/L on 2 measurements without acute illness) deserves a workup for the cause: occult chronic infection (dental, sinus, UTI, H. pylori), autoimmune disease, undiagnosed inflammatory conditions, metabolic syndrome, or even depression and sleep apnea. The marker is non-specific — it tells you inflammation is present, not where.

Newer inflammation markers (IL-6, GlycA, fibrinogen, NLR) provide complementary information but are not yet routine in primary care. hs-CRP remains the cheapest, most-validated entry point.